SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1507.0
(0.53%)
KRW 1507.0
(0.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 595.48 Million KRW | -70.23% |
| 2022 | 2 Billion KRW | -5.65% |
| 2021 | 2.11 Billion KRW | -92.47% |
| 2020 | 28.14 Billion KRW | 120.19% |
| 2019 | 12.78 Billion KRW | -30.75% |
| 2018 | 18.46 Billion KRW | -59.31% |
| 2017 | 45.36 Billion KRW | 2.68% |
| 2016 | 44.18 Billion KRW | -40.82% |
| 2015 | 74.66 Billion KRW | 186.77% |
| 2014 | 26.03 Billion KRW | -32.17% |
| 2013 | 38.38 Billion KRW | -19.64% |
| 2012 | 47.76 Billion KRW | 61.29% |
| 2011 | 29.61 Billion KRW | 11.59% |
| 2010 | 26.53 Billion KRW | 25.37% |
| 2009 | 21.16 Billion KRW | 31.83% |
| 2008 | 16.05 Billion KRW | -12.9% |
| 2007 | 18.43 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 4.55 Billion KRW | 664.12% |
| 2024 Q2 | 4.34 Billion KRW | -4.44% |
| 2023 Q1 | 1.51 Billion KRW | -24.33% |
| 2023 Q4 | 595.48 Million KRW | -49.18% |
| 2023 Q3 | 1.17 Billion KRW | -13.13% |
| 2023 FY | 595.48 Million KRW | -70.23% |
| 2023 Q2 | 1.34 Billion KRW | -10.89% |
| 2022 Q3 | 1.87 Billion KRW | -6.09% |
| 2022 FY | 2 Billion KRW | -5.65% |
| 2022 Q4 | 2 Billion KRW | 6.79% |
| 2022 Q1 | 2.1 Billion KRW | -0.89% |
| 2022 Q2 | 1.99 Billion KRW | -5.07% |
| 2021 Q4 | 2.11 Billion KRW | 76.08% |
| 2021 Q3 | 1.2 Billion KRW | 168.7% |
| 2021 Q2 | 448.09 Million KRW | -67.8% |
| 2021 Q1 | 1.39 Billion KRW | -95.06% |
| 2021 FY | 2.11 Billion KRW | -92.47% |
| 2020 Q3 | 27.79 Billion KRW | -6.42% |
| 2020 Q1 | 32.04 Billion KRW | 0.0% |
| 2020 Q2 | 29.7 Billion KRW | -7.32% |
| 2020 Q4 | 28.14 Billion KRW | 1.27% |
| 2020 FY | 28.14 Billion KRW | 120.19% |
| 2019 FY | 12.78 Billion KRW | -30.75% |
| 2019 Q1 | 17.33 Billion KRW | -6.12% |
| 2019 Q2 | 15.1 Billion KRW | -12.84% |
| 2019 Q3 | 14.28 Billion KRW | -5.43% |
| 2018 Q1 | 36.05 Billion KRW | -20.52% |
| 2018 Q4 | 18.46 Billion KRW | -2.84% |
| 2018 Q2 | 19.72 Billion KRW | -45.29% |
| 2018 FY | 18.46 Billion KRW | -59.31% |
| 2018 Q3 | 18.99 Billion KRW | -3.69% |
| 2017 FY | 45.36 Billion KRW | 2.68% |
| 2017 Q4 | 45.36 Billion KRW | -13.7% |
| 2017 Q3 | 52.57 Billion KRW | 1.62% |
| 2017 Q2 | 51.73 Billion KRW | 19.97% |
| 2017 Q1 | 43.11 Billion KRW | -2.41% |
| 2016 FY | 44.18 Billion KRW | -40.82% |
| 2016 Q4 | 44.18 Billion KRW | -20.87% |
| 2016 Q3 | 55.83 Billion KRW | 4.89% |
| 2016 Q2 | 53.23 Billion KRW | -25.78% |
| 2016 Q1 | 71.72 Billion KRW | -3.94% |
| 2015 Q2 | 44.85 Billion KRW | 0.0% |
| 2015 Q3 | 58.82 Billion KRW | 31.13% |
| 2015 Q4 | 74.66 Billion KRW | 26.93% |
| 2015 FY | 74.66 Billion KRW | 186.77% |
| 2014 FY | 26.03 Billion KRW | -32.17% |
| 2014 Q4 | 26.03 Billion KRW | 0.0% |
| 2014 Q1 | 38.39 Billion KRW | 0.02% |
| 2013 FY | 38.38 Billion KRW | -19.64% |
| 2013 Q4 | 38.38 Billion KRW | 0.33% |
| 2013 Q3 | 38.25 Billion KRW | -0.69% |
| 2013 Q2 | 38.52 Billion KRW | -3.13% |
| 2013 Q1 | 39.76 Billion KRW | -16.74% |
| 2012 Q1 | 36.93 Billion KRW | 24.73% |
| 2012 Q2 | 36.78 Billion KRW | -0.39% |
| 2012 Q3 | 36.89 Billion KRW | 0.28% |
| 2012 Q4 | 47.76 Billion KRW | 29.45% |
| 2012 FY | 47.76 Billion KRW | 61.29% |
| 2011 Q4 | 29.61 Billion KRW | 0.26% |
| 2011 Q2 | 29.78 Billion KRW | 9.51% |
| 2011 Q1 | 27.19 Billion KRW | 2.5% |
| 2011 Q3 | 29.53 Billion KRW | -0.84% |
| 2011 FY | 29.61 Billion KRW | 11.59% |
| 2010 Q2 | 24.68 Billion KRW | 16.72% |
| 2010 Q3 | 24.47 Billion KRW | -0.87% |
| 2010 Q4 | 26.53 Billion KRW | 8.42% |
| 2010 Q1 | 21.15 Billion KRW | -0.06% |
| 2010 FY | 26.53 Billion KRW | 25.37% |
| 2009 Q3 | 20.17 Billion KRW | 25.68% |
| 2009 Q1 | 16.05 Billion KRW | -0.0% |
| 2009 Q4 | 21.16 Billion KRW | 4.9% |
| 2009 Q2 | 16.05 Billion KRW | -0.0% |
| 2009 FY | 21.16 Billion KRW | 31.83% |
| 2008 Q2 | 16.05 Billion KRW | -0.0% |
| 2008 Q3 | 16.05 Billion KRW | -0.0% |
| 2008 Q4 | 16.05 Billion KRW | -0.0% |
| 2008 FY | 16.05 Billion KRW | -12.9% |
| 2008 Q1 | 16.05 Billion KRW | -12.89% |
| 2007 Q3 | 18.37 Billion KRW | 0.27% |
| 2007 FY | 18.43 Billion KRW | 0.0% |
| 2007 Q4 | 18.43 Billion KRW | 0.29% |
| 2007 Q1 | 18.27 Billion KRW | 0.0% |
| 2007 Q2 | 18.32 Billion KRW | 0.27% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 98.766% |
| Yuhan Corporation | 230.07 Billion KRW | 99.741% |
| Yuhan Corporation | 230.07 Billion KRW | 99.741% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 98.489% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 98.489% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 98.489% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 99.844% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 99.661% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 99.914% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.65% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.65% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.65% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 99.873% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 98.624% |
| HANDOK Inc. | 300.01 Billion KRW | 99.802% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 99.656% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | 98.058% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 99.25% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 99.671% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -150.072% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 99.592% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 99.11% |
| Boryung Corporation | 204.21 Billion KRW | 99.708% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | 98.481% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 99.498% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 99.301% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 99.301% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 99.873% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 99.747% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | 53.857% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | 5.781% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 99.342% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 98.71% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 98.71% |
| Korea United Pharm Inc. | 40.33 Billion KRW | 98.524% |
| CKD Bio Corp. | 146.92 Billion KRW | 99.595% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 99.873% |
| JW Holdings Corporation | 554.58 Billion KRW | 99.893% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 99.735% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 99.896% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 99.854% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 99.729% |
| JW Lifescience Corporation | 46.31 Billion KRW | 98.714% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 99.727% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 99.299% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | 97.756% |